Roger Léger

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^

Ulysses Pharmaceuticals Pvt Ltd. provides homeopathic modern medicines. It engages in the discovery and development of novel and safe antimicrobial agents for the treatment of severe and recurrent infections occurring in human. The company was founded in July 2001 and is headquartered in Kolkata, India.

ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada.

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

Ulysses Pharmaceuticals discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections. The company was founded in December 2001 by Suzanne Chamberland, Roger Léger, and François Malouin and is headquartered in Sherbrooke, Canada